Rejuvenation Technologies Inc. GTM brain

Rejuvenation Technologies is developing investigational mRNA telomere-extension therapies for patients with pulmonary fibrosis and other age-related diseases.

category

Telomere-targeted mRNA therapeutics

market profile

  • text: Short-telomere pulmonary fibrosis is the lead translational focus, with liver and hematologic programs also described.
  • text: Preclinical mouse results support further research but do not establish human efficacy or safety.
  • text: The homepage labels planned trials inactive, while the YC founder profile claims a first human subject; current trial status needs direct confirmation.

personas

  • title: Pulmonologist or interstitial lung disease trial investigator
    pains:
    • Progressive pulmonary fibrosis and limited options to restore lost lung function
    • Need clear patient eligibility and safety data for investigational treatments
  • title: Biopharma licensing or translational research leader
    pains:
    • Finding tissue-targeted delivery platforms with a plausible translational path
    • Assessing long-term safety and biological efficacy before committing to a program
  • title: Patient or caregiver affected by pulmonary fibrosis
    pains:
    • Progressive illness and uncertainty over available studies
    • Understanding whether a trial is active and appropriate

icp

  • text: Specialist pulmonary fibrosis centers and academic hospitals with clinical research capabilities are prospective trial stakeholders.
  • text: Biopharma and research organizations working on fibrotic disease or mRNA delivery are potential development partners; no commercial offer was verified.

message pillars

  • text: Target aging mechanisms through telomere biology.
  • text: Use transient modified mRNA to activate telomerase.
  • text: Focus development on disease areas with unmet need.

objections

  • objection: Does extending telomeres increase cancer risk?
    response: Transient activation is the proposed strategy; independent long-term human safety evidence remains necessary.
  • objection: Are trials recruiting now?
    response: The homepage says its listed trials are not active, while the YC profile states a first subject; confirm with the sponsor and trial registry.

competitors

  • name: Insilico Medicine
    why: Develops investigational rentosertib for idiopathic pulmonary fibrosis, an indication-level alternative.
  • name: Sierra Sciences
    website: https://en.wikipedia.org/wiki/Sierra_Sciences
    why: Historical telomerase activation research represents a related approach to telomere biology.

influencers

  • name: John Ramunas
    url: https://www.ycombinator.com/companies/rejuvenation-technologies-inc
    why: Founder and CEO with a published background in telomere extension.
  • name: Helen Blau
    url: https://www.rejuvenationtech.com/
    why: Stanford scientist, co-inventor and company advisor in telomere biology.

keywords

  • telomerase mRNA therapy
  • short telomere pulmonary fibrosis
  • telomere extension clinical trial
  • mRNA lipid nanoparticle lung delivery
  • liver fibrosis investigational treatment

voice

  • Scientific
  • Ambitious
  • Regenerative medicine focused

signals

  • text: A pulmonary center studies short-telomere-associated fibrosis or participates in investigational fibrosis trials.
  • text: A biopharma team is seeking tissue-targeted mRNA delivery or regenerative approaches in fibrosis.

pricing

model: unknown

motion

unknown

channels

  • Scientific publications
  • Research grants
  • Investor partnerships

confidence

medium

Founders

  • name: Glenn Markov
    title: Founder
    role: Founder
    bio: Stanford PhD Genetics (2018)
  • name: John Ramunas
    title: Founder
    role: Founder
    bio: John Ramunas, PhD, invented TERT mRNA telomere extension at Stanford in Helen Blau's lab - reversing a decade of telomere shortening in one treatment. 50+ granted patents across 7 families through 2046. Preclinical efficacy in 4 organ systems. FDA INTERACT cleared. Khosla Ventures seed. YC S18. Raising $10M seed extension ($2M wired) for 3 clinical trials - Phase I readout Q3 2027. Subject #1 in first human trial.

Back to YC companies